Epoetin Zeta

CHEMBL2108593 Phase 4 승인됨 Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This biosimilar form of erythropoietin stimulates red blood cell production to treat anemia in patients with kidney disease or undergoing chemotherapy. It works by binding to erythropoietin receptors on bone marrow cells.

치료 영역

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This biosimilar form of erythropoietin stimulates red blood cell production to treat anemia in patients with kidney disease or undergoing chemotherapy. It works by binding to erythropoietin receptors on bone marrow cells.

Yes, Epoetin Zeta is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108593. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.